DeepScribe, a San Francisco, CA-based AI-powered medical transcription platform, raised $30 million in Series A funding.
The round was led by Nina Achadjian at Index Ventures, with participation from Scale.ai CEO Alex Wang, Figma CEO Dylan Field, and existing investors Bee Partners, Stage 2 Capital, and 1984 Ventures.
This latest investment will accelerate DeepScribe’s growth, as it plans to continue to improve and transform medical documentation workflows and healthcare overall.
DeepScribe aims to deploy its technology to multiple large health systems, grow its engineering team and get its AI in the hands of more physicians.
Round: Series A
Funding Month: January 2022
Lead Investors: Nina Achadjian at Index Ventures
Additional Investors: Alex Wang, Dylan Field, Bee Partners, Stage 2 Capital, and 1984 Ventures
Company Website: https://www.deepscribe.ai/
Software Category: AI-powered medical transcription platform
About the Company: Founded in 2017, 2017 by Akilesh Bapu, Matthew Ko, and Kairui Zeng to unburden doctors from tedious data entry and allow them to focus on their patients. DeepScribe, an AI-powered medical transcription platform, brings the joy of care back to medicine by providing clinicians with a reliable, affordable, and secure medical scribe solution that eliminates the need to take notes during patient interactions or dictate notes between patients and after hours. To date, the company has saved physicians over 2.5 million minutes of documentation. In terms of reliability, Over the past 18 months, DeepScribe has scaled to more than 400 physicians around the United States and processed over half a million patient-physician conversations. DeepScribe says physicians encounter less than one correction per note on average after 20 days of usage.